Upload
dothuan
View
220
Download
4
Embed Size (px)
Citation preview
GLOBAL REGULATORY APPROACHES TO IMPROVE HEALTH CARE COLLABORATION / STRATEGIES / SOLUTIONS
Murray M. Lumpkin, M.D., M.Sc. Bill and Melinda Gates Foundation TOPRA Annual Symposium 2017 London, United Kingdom 02 October 2017
© Bill & Melinda Gates Foundation |
THE FOCUS OF OUR WORK IS THE PATIENT “THE PATIENT IS WAITING” – but which patients? All – or --
© Bill & Melinda Gates Foundation | 2
• Only patients who can pay for medical products?
• Only patients who live in a country for which there is a “business case” for medical products?
• Only patients with diseases for which there is a “business case” for medical products?
IMPROVE HEALTH CARE – DEVELOPING MEDICAL PRODUCTS
© Bill & Melinda Gates Foundation | 4
THINK GLOBALLY
ACT LOCALLY
There are some significant differences in disease burden and access to effective, safe, quality products in various parts of the world.
There are some significant similarities in disease burden and differences in access to effective, safe, quality products in various parts of the world.
What can we as regulatory professionals do to help address some of these disparities?
There’s a lot going on!
2 mil km2
THE DEMOCRATIC REPUBLIC OF CONGO IS ABOUT 2/3 THE SIZE OF WESTERN EUROPE
• Last formal census: 1984 • Estimated population is 70-80 M • 200 ethnic groups with major regional
linguistic variation • Life expectancy: 49.6 years • Infant mortality: 73.15/1,000 live births • 1400 miles of paved roads – ½ in
“good” condition
• TB causes more Disability Adjusted Life Years (DALYs) than Diabetes • Only one new product approved in 40 years for TB • In type II diabetes, 6 new products were approved in 2013 and 2014
© 2014 Bill & Melinda Gates Foundation
FACTS ABOUT THE GEOGRAPHIES Country Median Age
(2012) ¹ <5 mortality rate per 1000 births (2012) ¹
No of births per mother ² (2012)
Deaths from TB per 100,000 (2012) ¹
Deaths from cardiovascular disease per 100,000 (both sexes) [2012]³
% secondary school attendance Males (2008-2012) 4
% school attendance Females (2008-2012) 4
DRC 17 146 6.0 54 359.6 35.1 28.3 Kenya 19 124 4.5 22 205.0 39.5 41.6
Nigeria 18 73 6.0 16 266.5 54.2 54.3 UK 40 5 1.9 0.5 136 97.4 99.6 US 37 7 1.9 0.1 111.8 88.8 90.2
¹ WHO World Health Statistics 2014; ² WB country data 2014; ³ WHO NCD report 2014;4 UNICEF country statistics 2013
Population 2100 Population 2010
The changing shape of global population
http://www.viewsoftheworld.net/wp-content/uploads/2011/10/WorldPopulationAnimation.gif
Population 2080
The changing shape of global population
Disease burden… early neonatal mortality
Source: http://www.worldmapper.org/
Source: http://www.worldmapper.org/
Mismatch with available medical care…
Physicians
The good, the bad, and the ugly
© Bill & Melinda Gates Foundation | 21
THE GOOD -- Regulation done well - facilitates access and impact by assuring that products available are quality products whose claims are backed by independent evaluation of good science. Reg done well is thus a positive force for access to quality products with resultant positive impact on both the public health and the economic health of communities. THE BAD -- Regulation done poorly - retards access to quality products and has a negative impact on both the public health and the economic health of communities. THE UGLY -- Regulation not done at all - creates chaos both in public health and in the market place where products are of questionable quality and are not backed by science. Patients are exploited in a “buyer beware” dynamic that is a “rush to the bottom” when it comes to product quality, efficacy, and safety. There is access to items that purport to be medicines, and the impact on public health is highly negative.
REGULATION OF MEDICAL PRODUCTS
REGULATORY AND HTA ACTIVITIES IN HIGH INCOME COUNTRIES
ARE KEY STEPS
IN HEALTH PRODUCT ACCESS AND IMPACT
© Bill & Melinda Gates Foundation | 22
Delivery of product
Safety, Efficacy, and Quality data NRA Registration
Treatment Recommendation data
Might be helpful (more to do with clinical practice)
HTA / Payers (local or sub-local)
Surveil-lance (strong)
A C C E S S
I M P A C T
(disease, product safety, supply chain Integrity)
A P P R O V A L
REGULATORY AND OTHER ACTIVITIES IN LOW AND VERY LOW INCOME COUNTRIES
ARE KEY STEPS
IN GLOBAL HEALTH PRODUCT ACCESS AND IMPACT
© Bill & Melinda Gates Foundation | 23
Delivery of product (physical, transport, storage, theft, diversion)
Safety, Efficacy, and Quality data
1st regi-stration
WHO PQ
NRA Regi- stration
Treatment Recommendation data
WHO and other Treatment Recommendations - mandatory
Procure-ment (UN, multi-nationals and local)
Surveil-lance (weak to non-existent)
A C C E S S
I M P A C T
(disease, product safety, supply chain Integrity)
A P P R O V A L
© Bill & Melinda Gates Foundation | 24
REGISTRATION VERSUS TREATMENT RECOMMENDATION
REGISTRATION / PQ LISTING
• Manufacturing Quality and Consistency • Safety (clinical / pre-clinical) • Efficacy in clinical trials settings • Clinical trials of a certain size, ability to
determine if an effect is due to the product • Known benefit (efficacy) / known risk profile • Risk of the unknown about the product vs
known risk of the disease being treated • Country suitability with respect to product
presentation (stability in climate/transport and utility in health care system) and labeling
TREATMENT RECOMMENDATION (WHO “policy” or “normative guidance”)
• Safety in population using product • Efficacy / Effectiveness in population using
product • Impact of product use on public health • Feasibility of product implementation • Sometimes health economic evaluations (cost
effectiveness) (also done by procurers) • Role of product in context of existing
interventions • Broader perspectives
• Equity • Community acceptability (custom,
acceptability)
© Bill & Melinda Gates Foundation | 25
MEDICINES AND VACCINES REGISTRATION DATA
1st RA approval time
PQ approval time
Spread in RA submissions
SSAfrica approval time Median (months)
Medicines
Vaccines 15 16 78
SRA 10 months 4 52 11
NRA ~12 27 ~24 ~18
16
~12 16 N/A N/A
SRA
NRA
A
B
D C
SRA: Stringent Regulatory Authority (e.g. US FDA, EMA); NRA: National Regulatory Authority (e.g. India CDSCO, China FDA) (WHO classifications)
Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization Vincent Ahonkhai, Samuel F. Martins, Alexandre Portet, Murray Lumpkin, Dan Hartman. Integrated Development – Global Health, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America
PLoS ONE 11(11): e0166515. doi:10.1371/journal.pone.0166515 16 Nov 2016
26
THE PROBLEM: EXAMPLE OF LONG SUBMISSION SPREADS Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
SRA A SRA B NRA A NRA B NRA C NRA D NRA E NRA F NRA G NRA H NRA I NRA J NRA K NRA L NRA M NRA N NRA O NRA P NRA Q NRA R NRA S NRA T NRA U
Total time (yrs) Reg. Authority
0.5
0.7
1.8
4.9
1.7
2.6
2.6
1.0
0.6
0.5
4.3
>5.0
0.7
1.2
2.0
0.3
0.9
3.3
1.0
1.0
>2.0
>1.7
>1.7
Submission
Approval
Source: BMGF Regulatory Strategy study © Bill & Melinda Gates Foundation |
© Bill & Melinda Gates Foundation | 27
(1)RELIANCE
(2)RE-ENGINEERING
(3)REGIONALISATION
STRATEGIC APPROACH
WHO PQ
1 For Rx and Dx, previous regulatory approval is not required for PQ submission. This would include products that are manufactured at different sites or for other reasons are not the same version as that approved by an SRA. For Vx, previous regulatory approval by a “vaccine functional” NRA is required.
NRA1
(generally in manufacturing country; generally
established products)
Full PQ assessment
SRA (includes EU Art 58,
Swissmedic MAGHP, and US FDA tropical voucher)
(established or innovative
products)
Abridged PQ assessment
Medicines, meeting major public health need, but not in scope for PQ - Ad hoc WHO PQ support of local registration, including support for joint reviews
being undertaken by RECs and other groups
NRA / REC (marketing country/
- ies)
PQ Collaborative Procedure
Joint Review Procedure (as part of PQ assessment process)
(not as part of PQ assessment process)
EUAL ERP
Interim, time-limited tendering allowed,
while PQ or SRA assessment proceeds
OVERVIEW OF FACILITATED REGISTRATION PATHWAYS
1
Current activities Developing activities
STATISTICS ON PQ COLLABORATIVE PROCEDURE (MEDICINES)
Key facts
30 countries plus CARICOM enrolled in the collaborative procedure
54 medicines registered
185 registrations
74 days as a median time for local registration
Country # of registrations Manufacturer # of registrations Therapeutic area
25 16 16 15 14 13
11 10 10 10 9 9
5 5 4 4 4
2 2 1
Nigeria Tanzania
Zambia Zimbabwe
Ukraine Malawi Ghana
Botswana Ethiopia Namibia
Philippines Uganda
Armenia Kenya
DRC Madagascar Mozambique
Cameroon Kyrgyzstan
Burkina Faso
100
26
21
16
7
5
3
2
2
1
1
Macleods Ph.
Cipla
Hetero Labs
Jai Pharma
Strides
Mylan Lab.
Ajanta Ph.
Cadila Ph.
DNDi*
Dong-A ST Co
Eisai Co
*Cipla Ltd is the supplier and is responsible for the product
84
39
28
22
12
HIV
TB
Malaria
Rep. Health
NTD
© Bill & Melinda Gates Foundation | 30 End of 2016
31
32
THE AMRH VISION
54 countries 1 continent
African Medicines Agency
5 regions
IGAD / AMU / CEN-SAD
ECCAS OCEAC
ECOWAS UEMOA EAC
SADC COMESA
© Bill & Melinda Gates Foundation |
33
AMRH - IMPACT IN EAST AFRICA Full implementation on track
Launched the regional EAC product registration system in Jan 2015 Using Expression of Interest approach First joint regional review in Oct 2015 with technical support from WHO and Swissmedic Second review in May 2016 Ethiopia joined for third review in Aug 2016 and subsequent review sessions, also South
Sudan has now joined (technical support by WHO and Swissmedic) Regulatory harmonization Model Law adopted by African Union Heads of State in Jan 2016
32 products have been reviewed (none previously PQed), with 4 accepted (rest awaiting com respon) Manufacturers: Sandoz (13), Mylan (5), Hetero (3), Roche (4), Bayer (1), Janssen (1), Merck (1),
EAC-based (4) TAs: Cancer (7), Cardiovascular (10), Diuretic (2), Epilepsy (2), HIV (2), Antibiotics (2),
Antidepressants (1), Herpes (1), Diabetes (2), TB (1, bedaquiline), others (2)
Expanding to other product streams (Vaccines) and regulatory functions (Pharmacovigilance, clinical trials) and geographies (west Africa – ECOWAS, and southern Africa – SADC/ZaZiBoNa)
© Bill & Melinda Gates Foundation |
• Caribbean Regulatory System – PAHO – CARICOM countries • Joined Collaborative Process as first regional regulatory organization • 11 recommendations (joint assessments; reliance on PQ or PAHO
regional reference) – first one now with national authorization (less than 60 days from joint review) – countries using fast track approach
• China CFDA – WHO and CFDA efforts to make China an NRA on whose work products (inspections, scientific reviews) WHO can rely (ML4) – focus initially on vaccines (2019) and generic drugs thereafter
• New WHO guidances on “Good Reliance Practices” • Pharmacovigilance strategies oriented to new products being initially
introduced into LICs
© Bill & Melinda Gates Foundation | 34
OTHER REGULATORY SYSTEMS INITIATIVES
• WHO’s Coalition of Interested Technical Partners as approach to Regulatory Systems Strengthening in LICs – focused initially on local PV, local manufacturing oversight, generic drugs, and local supply chain integrity – using new WHO NRA global benchmarking tool
• Substandard and falsified products – WHO database and investigations • Rationalizing local CMC requirements • Rationalizing local vaccine variation processes • Regulatory processes in public health emergencies (CTAs, emergency
authorizations, emergency use PV)
© Bill & Melinda Gates Foundation | 35
OTHER REGULATORY SYSTEMS INITIATIVES
THANK YOU
© Bill & Melinda Gates Foundation | 36